Business
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
New data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases. FOSTER CITY,
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\nNew data reinforce Mirum’s commitment to advancing therapies and improving the lives of patients across diverse rare liver diseases.\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that multiple presentations featuring data from its LIVMARLI (maralixibat) and volixibat clinical programs will be shared during the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 7-11, 2025, in Washington, D.C.\n\nThe presentations highlight Mirum’s continued progress in expanding the scientific and clinical foundation for new approaches to treating adult and pediatric rare liver diseases, including new findings from the VANTAGE trial and real-world studies.\n\nOral Presentation\nA key highlight at this year’s meeting will be an oral presentation featuring additional analyses from the VANTAGE trial evaluating volixibat in adults with primary biliary cholangitis (PBC).\n\nAbstract #0215: Volixibat Leads to Improvements in Fatigue and Sleep for Adults with Primary Biliary Cholangitis: Data from VANTAGE Trial\nMonday, November 10, 2025, 3:00-3:15 pm during the ‘Novel Therapies and Monitoring in Cholestatic Liver Disease’ session, Room 145, Level 1, Convention Center\n\nPresented by Kris Kowdley, Liver Institute Northwest, Seattle, Washington, USA\n\nPoster Presentations\nIn addition to new volixibat data, several abstracts highlight real-world experience with maralixibat and insights from genetic testing in cholestasis.\n\nAbstract #4411: Maralixibat, an Ileal Bile Acid Transporter Inhibitor, Reduces Cholestatic Pruritus in PSC: Real-World Experience\nMonday, November 10, 2025, 1:00-2:00 pm\nPosters and Exhibit Hall, Level 2, Convention Center\n\nPresented by Dr. Adrielly Martins, University of Miami, Florida, USA\n\nAbstract #4412: Clinical Utility of Comprehensive Genetic Testing in Adult Cholestasis: Insights from 856 Panel Tests\nMonday, November 10, 2025, 1:00-2:00 pm\nPosters and Exhibit Hall, Level 2, Convention Center\n\nPresented by Dr. Tiziano Pramparo, Mirum Pharmaceuticals, Inc., Foster City, California, USA\n\nAbstract #4415: Exploring the Role of Ileal Bile Acid Transporter Inhibitors, Like Volixibat, in the Regulation of IL-31 and Serum Bile Acids in Patients with Primary Biliary Cholangitis: P...